How the knowledge of fracture risk might influence adherence to oral therapy of osteoporosis in Italy: the ADEOST study

[1] Cooper C(2001)Development panel on osteoporosis prevention diagnosis and therapy JAMA 285 785-795

[2] Atkinson EJ(1992)Incidence of clinically diagnosed vertebral fractures: a population-based study in Rochester, Minnesota, 1985–1989 J Bone Miner Res 7 221-227

[3] O’Fallon WM(1999)Health burden of hip and other fractures in Australia beyond 2000. Projections based on the Geelong Osteoporosis Study Med J Aust 170 467-470

[4] Sanders KM(2002)Epidemiology and outcomes of osteoporotic fractures Lancet 359 1761-1777

[5] Nicholson GC(2004)An estimate of the worldwide prevalence, mortality and disability associated with hip fracture Osteoporos Int 15 897-902

[6] Ugoni AM(2013)Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA) Arch Osteoporos 8 136-57

[7] Cummings SR(2013)Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the Committee of Scientific Advisors of the International Osteoporosis Foundation (IOF). European guidance for the diagnosis and management of osteoporosis in postmenopausal women Osteoporos Int 24 23-1493

[8] Melton LJ(2007)Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis Mayo Clin Proc 82 1450-573

[9] Johnell O(2007)Unmet needs in fracture prevention: new European guidelines for the investigation and registration of therapeutic agents Osteoporos Int 18 569-2918

[10] Kanis JA(2013)Interventions to improve osteoporosis medication adherence and persistence: a systematic review and literature appraisal by the ISPOR Medication Adherence and Persistence Special Interest Group Osteoporos Int 24 2907-3259

[1] Cooper C(2001)Development panel on osteoporosis prevention diagnosis and therapy JAMA 285 785-795

[2] Atkinson EJ(1992)Incidence of clinically diagnosed vertebral fractures: a population-based study in Rochester, Minnesota, 1985–1989 J Bone Miner Res 7 221-227

[3] O’Fallon WM(1999)Health burden of hip and other fractures in Australia beyond 2000. Projections based on the Geelong Osteoporosis Study Med J Aust 170 467-470

[4] Sanders KM(2002)Epidemiology and outcomes of osteoporotic fractures Lancet 359 1761-1777

[5] Nicholson GC(2004)An estimate of the worldwide prevalence, mortality and disability associated with hip fracture Osteoporos Int 15 897-902

[6] Ugoni AM(2013)Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA) Arch Osteoporos 8 136-57

[7] Cummings SR(2013)Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the Committee of Scientific Advisors of the International Osteoporosis Foundation (IOF). European guidance for the diagnosis and management of osteoporosis in postmenopausal women Osteoporos Int 24 23-1493

[8] Melton LJ(2007)Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis Mayo Clin Proc 82 1450-573

[9] Johnell O(2007)Unmet needs in fracture prevention: new European guidelines for the investigation and registration of therapeutic agents Osteoporos Int 18 569-2918

[10] Kanis JA(2013)Interventions to improve osteoporosis medication adherence and persistence: a systematic review and literature appraisal by the ISPOR Medication Adherence and Persistence Special Interest Group Osteoporos Int 24 2907-3259